Literature DB >> 17699461

A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases.

Laura Barisoni1, H William Schnaper, Jeffrey B Kopp.   

Abstract

A spectrum of proteinuric glomerular diseases results from podocyte abnormalities. The understanding of these podocytopathies has greatly expanded in recent years, particularly with the discovery of more than a dozen genetic mutations that are associated with loss of podocyte functional integrity. It is apparent that classification of the podocytopathies on the basis of morphology alone is inadequate to capture fully the complexity of these disorders. Herein is proposed a taxonomy for the podocytopathies that classifies along two dimensions: Histopathology, including podocyte phenotype and glomerular morphology (minimal-change nephropathy, focal segmental glomerulosclerosis, diffuse mesangial sclerosis, and collapsing glomerulopathy), and etiology (idiopathic, genetic, and reactive forms). A more complete understanding of the similarities and differences among podocyte diseases will help the renal pathologist and the nephrologist communicate more effectively about the diagnosis; this in turn will help the nephrologist provide more accurate prognostic information and select the optimal therapy for these often problematic diseases. It is proposed that final diagnosis of the podocytopathies should result from close collaboration between renal pathologists and nephrologists and should whenever possible include three elements: Morphologic entity, etiologic form, and specific pathogenic mechanism or association.

Entities:  

Mesh:

Year:  2007        PMID: 17699461     DOI: 10.2215/CJN.04121206

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  103 in total

Review 1.  FSGS: from pathogenesis to the histological lesion.

Authors:  Andrea Angioi; Antonello Pani
Journal:  J Nephrol       Date:  2016-07-09       Impact factor: 3.902

2.  Familial collapsing focal segmental glomerulosclerosis.

Authors:  V Liakopoulos; A Huerta; S Cohen; M R Pollak; R A Sirota; K Superdock; G B Appel
Journal:  Clin Nephrol       Date:  2011-04       Impact factor: 0.975

3.  MYO1E mutations and childhood familial focal segmental glomerulosclerosis.

Authors:  Caterina Mele; Paraskevas Iatropoulos; Roberta Donadelli; Andrea Calabria; Ramona Maranta; Paola Cassis; Simona Buelli; Susanna Tomasoni; Rossella Piras; Mira Krendel; Serena Bettoni; Marina Morigi; Massimo Delledonne; Carmine Pecoraro; Isabella Abbate; Maria Rosaria Capobianchi; Friedhelm Hildebrandt; Edgar Otto; Franz Schaefer; Fabio Macciardi; Fatih Ozaltin; Sevinc Emre; Tulin Ibsirlioglu; Ariela Benigni; Giuseppe Remuzzi; Marina Noris
Journal:  N Engl J Med       Date:  2011-07-14       Impact factor: 91.245

Review 4.  Glomerular diseases: FSGS.

Authors:  Bhadran Bose; Daniel Cattran
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

Review 5.  Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis.

Authors:  Kirk N Campbell; James A Tumlin
Journal:  Am J Nephrol       Date:  2018-05-31       Impact factor: 3.754

6.  MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.

Authors:  Jeffrey B Kopp; Michael W Smith; George W Nelson; Randall C Johnson; Barry I Freedman; Donald W Bowden; Taras Oleksyk; Louise M McKenzie; Hiroshi Kajiyama; Tejinder S Ahuja; Jeffrey S Berns; William Briggs; Monique E Cho; Richard A Dart; Paul L Kimmel; Stephen M Korbet; Donna M Michel; Michele H Mokrzycki; Jeffrey R Schelling; Eric Simon; Howard Trachtman; David Vlahov; Cheryl A Winkler
Journal:  Nat Genet       Date:  2008-09-14       Impact factor: 38.330

7.  Collapsing focal segmental glomerulosclerosis: Current concepts.

Authors:  Muhammed Mubarak
Journal:  World J Nephrol       Date:  2012-04-06

Review 8.  Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults.

Authors:  Mirco Belingheri; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-03       Impact factor: 3.902

9.  Association of histologic variants in FSGS clinical trial with presenting features and outcomes.

Authors:  Vivette D D'Agati; Joan M Alster; J Charles Jennette; David B Thomas; James Pullman; Daniel A Savino; Arthur H Cohen; Debbie S Gipson; Jennifer J Gassman; Milena K Radeva; Marva M Moxey-Mims; Aaron L Friedman; Frederick J Kaskel; Howard Trachtman; Charles E Alpers; Agnes B Fogo; Tom H Greene; Cynthia C Nast
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 8.237

10.  Collapsing Glomerulopathy: A Single Centre Clinicopathologic Study of Seven Years.

Authors:  Kamal V Kanodia; Aruna V Vanikar; Rashmi D Patel; Kamlesh S Suthar; Lovelesh K Nigam; Himanshu V Patel; Vivek Kute; Hargovind L Trivedi
Journal:  J Clin Diagn Res       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.